research Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.
5-alpha reductase inhibitors are generally safe but can cause sexual side effects and require patient education on risks.
Search
for
Sort by
Research
630-660 / 1000+ results
research Imaging prostate cancer (PCa) with [99m Tc(CO)3 ]finasteride dithiocarbamate
A new compound was effective for imaging prostate cancer in rats.
research Ejaculatory dysfunction in the treatment of lower urinary tract symptoms
Treatments for urinary symptoms often cause ejaculatory problems.
research Tamoxifen for flutamide/finasteride-induced gynecomastia
Tamoxifen effectively treats gynecomastia without causing impotence.
research Association of breast cancer in men with exposure to 5-α reductase inhibitors: A RADAR report.
Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.
research New Finasteride Trial Results Aim To Curb Controversy
research Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates
A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
research Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System
Oral finasteride may cause more sexual side effects than expected, possibly due to negative publicity and reporting bias.
research Lower Urinary Tract Symptoms in the Elderly Male: Choosing Wisely
research Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.
research Reply to: “Tofacitinib for the treatment of severe alopecia areata and variants”
More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
research Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases
Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
research Attenzione divisa nei pazienti con cerebrolesione acquisita
Finasteride may cause sexual and psychological side effects by affecting an enzyme related to epinephrine.
research [Finasteride--ris of "unintentional doping"].
research Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
research Pharmacokinetics and Relative Bioavailability of Finasteride Tablets in Human
The two brands of finasteride tablets work the same in the body.
research Prescription Pattern of Tofacitinib for Alopecia Areata Among the Dermatologists in Saudi Arabia: A Cross-Sectional Study
Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.
research Paper 2. Epigallocatechin Gallate and Tannic Acid Based Formulations of Finasteride for Dermal Administration and Chemoembolization
Topical finasteride with EGCG or TA improves drug release and dermal uptake, potentially treating hair loss effectively.
research Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
STS01 1% effectively promotes hair regrowth with minimal side effects.
research The Effects of Oral 5-alpha Reductase Inhibitors on Penile Intracavernosal Pressures and Penile Morphology in Rat Model.
Oral finasteride and dutasteride may negatively affect erectile function in rats.
research Potential synergistic effects of Haedoksamul-tang and Finasteride of on 5α-reductase inhibition and proliferation of human follicle dermal papilla cells
HST and HST/F promote hair growth and may help treat alopecia.
research Luncheon Symposium (LS) : Update on the efficacy and safety of dutasteride in the management of androgenetic alopecia
Dutasteride is effective and safe for treating common hair loss, and it's more potent than finasteride, leading to better hair growth and thickness.
research The preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice
Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.
research Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
research THE HUMAN HAIR FOLLICLE AS SENTINEL FOR DRUGS EVALUATION: DEMONSTRATION OF TETRACYCLINE ADHESION TO HAIR FOLLICLE AS PROPOSED MECHANISM IN DYSFUNCTIONAL HAIR LOSS
Tetracycline can stick to hair follicles and potentially cause hair loss.
research Advances in Transdermal Delivery Systems for Treating Androgenetic Alopecia
Transdermal delivery systems show promise for treating hair loss by delivering drugs directly through the skin.
research Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide (The EAT-Proxa Biochemical AndroCoV-Trial)
Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
research Systematic review – alopecia areata and tofacitinib in paediatric patients
Tofacitinib may help treat hair loss in children with alopecia areata.
research Reply by the authors
Dutasteride may help prevent prostate cancer, but more research is needed.
research PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY
Finasteride reduces PSA levels by around 40-50% in BPH patients.